Liminatus Pharma (LIMN) Return on Assets (2025 - 2026)
Liminatus Pharma (LIMN) posted Return on Assets of 0.02% for Q1 2026, up 28.59% sequentially from 0.03% in Q4 2025.
Liminatus Pharma (LIMN) Return on Assets (2025 - 2026) Analysis & Trends
Liminatus Pharma has reported Return on Assets for 2 years, with the latest figure at 0.02% in Q1 2026.
- Quarterly Return on Assets changed N/A year-over-year to 0.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (changed N/A YoY) and the FY2025 annual result came in at 0.02%, changed N/A from the prior year.
- Return on Assets grew to 0.02% in Q1 2026 per LIMN's latest filing, from 0.03% in the prior quarter.
- Over five years, Return on Assets peaked at 0.02% in Q3 2025 and troughed at 0.03% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.00% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.00% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.00% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.00% |
| 10 | Liminatus Pharma | 5.46 Mn | 5.46 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.02% |
| Dec 31, 2025 | -0.03% |
| Sep 30, 2025 | -0.02% |